Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?

Autor: Elise Timon-David, Carla Perez, Anne Rodallec

Publikováno v: Pharmaceutics, Vol 14, Iss 11, p 2326 (2022)

While the number of oncology-related nanotherapeutics and immunotherapies is constantly increasing, cancer patients still suffer from a lack of efficacy and treatment resistance. Among the investigated strategies, patient selection and combinations a

Externí odkaz: https://doaj.org/article/9531eae4c7a646fba35711cfc1636fd8

Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer

Autor: Guillaume Sicard, Clément Paris, Sarah Giacometti, Anne Rodallec, Joseph Ciccolini, Palma Rocchi, Raphaëlle Fanciullino

Publikováno v: Pharmaceutics, Vol 12, Iss 12, p 1166 (2020)

Prostate cancer (PCa) is the second most common cancer in men worldwide and the fifth leading cause of death by cancer. The overexpression of TCTP protein plays an important role in castration resistance. Over the last decade, antisense technology ha

Externí odkaz: https://doaj.org/article/e0a55ff105ca4193996df2263157e9d7

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.

Autor: Thi Huyen Tram Nguyen, Jérémie Guedj, Xavier Anglaret, Cédric Laouénan, Vincent Madelain, Anne-Marie Taburet, Sylvain Baize, Daouda Sissoko, Boris Pastorino, Anne Rodallec, Géraldine Piorkowski, Sara Carazo, Mamoudou N Conde, Jean-Luc Gala, Joseph Akoi Bore, Caroline Carbonnelle, Frédéric Jacquot, Hervé Raoul, Denis Malvy, Xavier de Lamballerie, France Mentré, JIKI study group

Publikováno v: PLoS Neglected Tropical Diseases, Vol 11, Iss 2, p e0005389 (2017)

BACKGROUND:In 2014-2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drug

Externí odkaz: https://doaj.org/article/7f6efdf3b05345baa7f586719e1ce176

Docetaxel–trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer

Autor: Fanny Bouquet, Sarah Giacometti, Joseph Ciccolini, Bruno Lacarelle, Ariel Savina, Anne Rodallec, Jean Michel Brunel, Raphaelle Fanciullino, Helene Maccario, Florian Correard, Eric Mas, Caroline Orneto

Publikováno v: International Journal of Nanomedicine
International Journal of Nanomedicine, Dove Medical Press, 2018, 13, pp.3451-3465. ⟨10.2147/IJN.S162454⟩
International Journal of Nanomedicine, 2018, 13, pp.3451-3465. ⟨10.2147/IJN.S162454⟩

Background Trastuzumab plus docetaxel is a mainstay to treat HER2-positive breast cancers. However, developing nanoparticles could help to improve the efficacy/toxicity balance of this doublet by improving drug trafficking and delivery to tumors. Thi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ad8cb7ad3b9709f53027c302e3d9d24
http://europepmc.org/articles/PMC6014390

Population modeling of tumor growth curves, the reduced Gompertz model and prediction of the age of a tumor

Autor: Raphaelle Fanciullino, Clair Poignard, Sebastien Benzekry, Cristina Vaghi, Michalis Mastri, Anne Rodallec, Jonathan P. Mochel, John M.L. Ebos, Joseph Ciccolini

Publikováno v: PAGE 2019 Twenty-eighth meeting
PAGE 2019 Twenty-eighth meeting, Jun 2019, Stockholm, Sweden
Mathematical and Computational Oncology
Mathematical and Computational Oncology, pp.87-97, 2019, ⟨10.1007/978-3-030-35210-3_7⟩
Mathematical and Computational Oncology ISBN: 9783030352097
ISMCO

International audience; Quantitative analysis of tumor growth kinetics has been widely carried out using mathematical models. In the majority of cases, individual or average data were fitted. Here, we analyzed three classical models (exponential, log

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::589f6baac997f66b1537c434c29d0a90
https://hal.archives-ouvertes.fr/hal-02424578/document